Drug Profile
Crohn's disease therapeutic - Eli Lilly and Company
Latest Information Update: 30 May 2016
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Crohn's disease
Most Recent Events
- 23 Jan 2014 Phase-I clinical trials in Crohn's disease in USA (unspecified route)